Separation of drug and devices from food and cosmetics was never recommended by Lasagna Committee. The Nov. 5 issue of "The Pink Sheet" (T&G-3) implied that former FDA Commissioner Arthur Hull Hayes said that the Lasagna Committee had recommended a split up of the FDA centers. In a Nov. 26 letter to "The Pink Sheet," committee chairman Louis Lasagna, MD, states that "no such recommendations were ever entertained by the Lasagna Committee".
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.